Abstract: Described herein are compositions and methods for inhibiting HIV integrase activity. Also described are methods of identifying agents that inhibit HIV integrase for use in treating or preventing HIV. Also disclosed are methods of identifying agents that inhibit HIV viral mutants that are resistant to integrase inhibitors.
Type:
Grant
Filed:
March 4, 2014
Date of Patent:
June 21, 2016
Assignees:
Integratech Proteomics, LLC, National Institutes of Health
Abstract: Described herein are compositions and methods for inhibiting HIV integrase activity. Also described are methods of identifying agents that inhibit HIV integrase for use in treating or preventing HIV. Also disclosed are methods of identifying agents that inhibit HIV viral mutants that are resistant to integrase inhibitors.
Type:
Application
Filed:
March 4, 2014
Publication date:
July 3, 2014
Applicants:
The United Sates of America, as Represented by the Secretary, Department of Health and Human Service, Integratech Proteomics, LLC
Abstract: Described herein are compositions and methods for inhibiting HIV integrase activity. Also described are methods of identifying agents that inhibit HIV integrase for use in treating or preventing HIV. Also disclosed are methods of identifying agents that inhibit HIV viral mutants that are resistant to integrase inhibitors.
Type:
Grant
Filed:
March 18, 2010
Date of Patent:
March 25, 2014
Assignees:
Integratech Proteomics, LLC, The United States of America, as represented by the Secretary of the Department of Health and Human Services
Abstract: Described herein are controlled release hybrid systems and methods of use thereof. In certain embodiments, the controlled release hybrid systems can be used to screen for interactions between candidate molecules. In addition, these controlled release hybrid systems can be modified to screen for chemical inhibitors of interacting candidate molecules. In another embodiment, the controlled release hybrid systems described herein can be modified to screen for mutant molecules (e.g., peptides, proteins, polypeptides, portions of proteins, portions of polypeptides, or any combination thereof) when compared to candidate molecules that were previously shown to interact. Upon identifying these mutant molecules, the controlled release hybrid systems can be further utilized to identify peptide, chemicals, or a combination thereof that potentially act as inhibitors of these mutant molecules. In this embodiment, the controlled release systems can be readily modified for personalized medication applications.
Abstract: Described herein are compositions and methods for inhibiting HIV integrase activity. Also described are methods of identifying agents that inhibit HIV integrase for use in treating or preventing HIV. Also disclosed are methods of identifying agents that inhibit HIV viral mutants that are resistant to integrase inhibitors.
Type:
Application
Filed:
March 18, 2010
Publication date:
April 19, 2012
Applicants:
The United States of America, as Represented by the Secretary, Dept. of Health and Human Services, INTEGRATECH PROTEOMICS, LLC
© 2025 Justia
